Meet the Company Aiming to Treat Obesity with Magic Mushrooms

Rob Tessarolo, CEO of NeonMind Biosciences, highlights how psychedelics such as psilocybin may combat maladaptive eating habits.

NeonMind Biosciences is a biopharmaceutical company focussing their effort on psychedelic drug development. The company is now part of a huge push for psychedelic initiatives in Canada, with many talented individuals and organisations flourishing within the country. However, what sets NeonMind apart from the crowd is their primary aim: to use psilocybin as a treatment for obesity.

CEO and president Rob Tessarolo has an extensive background in drug development, with nearly 25 years experience in the pharmaceutical industry. He joined NeonMind in January, and is now setting the direction for the organisation and executing the strategic plan.

Psilocybin for Obesity

Tessarolo tells Psychedelic Spotlight there is still much uncertainty regarding the ways that psychedelics can be regulated. But NeonMind are aiming to demonstrate, in large-scale trials, the safety and efficacy of psychedelic medicine, which will hopefully facilitate their regulation by the FDA.